5 mins to read
Rapalogs: unraveling the journey from Easter Island to human trials
Dennis Yamashita, PhD, our former EVP of Chemistry and Chair of the Board of our PipeCo, Tornado Therapeutics, shares his first-hand witness of the evolution of Rapamycin; it was discovered on Easter Island and has evolved into a vital immunosuppressant and cancer treatment through its chemical relatives, rapalogs. The science is promising for new applications, such as treating and preventing diseases of aging.
6 mins to read
My journey — developing therapies to extend healthspan
Our former EVP of Drug Discovery, Georg C. Terstappen, shares how his passion drove him to embark on what became a 30-year journey through the biopharmaceutical industry, and why he has chosen to continue his journey with Cambrian. He also highlights the remarkable progress of Isterian, one of our PipeCo’s that he heads, and its promising lead-stage TG2 inhibitor which offers a compelling path forward for IPF.
Keep up with Cambrian!
Subscribe to receive alerts about our latest blog posts, press releases, and newsletters. Don't worry, you can always manage these preferences later to ensure you receive the updates that interest you the most.
Subscribe to receive alerts about our latest blog posts, press releases, and newsletters. Don't worry, you can always manage these preferences later, or sign up here for specific updates, to ensure you receive the updates that interest you the most.